Radical Concurrent Chemoradiotherapy With DDP/5-FU and PD-1 Antibody for Non-metastatic Rectal Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 12, 2024

Primary Completion Date

April 20, 2026

Study Completion Date

February 28, 2027

Conditions
Rectal Squamous Cell Carcinoma
Interventions
COMBINATION_PRODUCT

PD-1 and CRT

Chemotherapy (/3w): 1)DDP 75 mg/m2, d1, intravenous infusion; 2)5-FU 1000 mg/m2, d1-4, continuous pumping intravenously; Immunotherapy (/3w): PD-1 monoclonal antibody(sintilimab) 200mg, d1, intravenous infusion; Radiotherapy (at 3rd week after first time of chemotherapy):Daily single dose of 2Gy, with a total dose of 50-54GY.

Trial Locations (1)

Unknown

RECRUITING

Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sixth Affiliated Hospital, Sun Yat-sen University

OTHER